D
68.10
-2.59 (-3.66%)
| Previous Close | 70.69 |
| Open | 69.72 |
| Volume | 3,930,510 |
| Avg. Volume (3M) | 5,251,126 |
| Market Cap | 26,560,106,496 |
| Price / Earnings (TTM) | 32.58 |
| Price / Earnings (Forward) | 26.81 |
| Price / Sales | 5.82 |
| Price / Book | 9.38 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | 12.90% |
| Operating Margin (TTM) | 12.91% |
| Diluted EPS (TTM) | 1.33 |
| Quarterly Revenue Growth (YOY) | 12.50% |
| Quarterly Earnings Growth (YOY) | -28.00% |
| Total Debt/Equity (MRQ) | 113.97% |
| Current Ratio (MRQ) | 1.50 |
| Operating Cash Flow (TTM) | 964.10 M |
| Levered Free Cash Flow (TTM) | 509.04 M |
| Return on Assets (TTM) | 5.97% |
| Return on Equity (TTM) | 23.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | DexCom, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.2
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -0.20 |
|
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 97.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Canaccord Genuity, 39.50%) | Buy |
| Median | 85.00 (24.82%) | |
| Low | 72.00 (Barclays, 5.73%) | Sell |
| Average | 84.63 (24.27%) | |
| Total | 7 Buy, 1 Sell | |
| Avg. Price @ Call | 69.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 84.00 (23.35%) | Buy | 66.31 |
| BTIG | 09 Mar 2026 | 85.00 (24.82%) | Buy | 68.74 |
| 25 Feb 2026 | 85.00 (24.82%) | Buy | 73.16 | |
| Truist Securities | 17 Feb 2026 | 80.00 (17.47%) | Buy | 70.43 |
| Barclays | 13 Feb 2026 | 72.00 (5.73%) | Sell | 70.02 |
| 12 Jan 2026 | 71.00 (4.26%) | Sell | 70.98 | |
| Canaccord Genuity | 13 Feb 2026 | 95.00 (39.50%) | Buy | 70.02 |
| Mizuho | 13 Feb 2026 | 90.00 (32.16%) | Buy | 70.02 |
| Wells Fargo | 13 Feb 2026 | 85.00 (24.82%) | Buy | 70.02 |
| Bernstein | 09 Jan 2026 | 86.00 (26.28%) | Buy | 67.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BROWN MICHAEL JON | - | 66.34 | -1,700 | -112,778 |
| Aggregate Net Quantity | -1,700 | |||
| Aggregate Net Value ($) | -112,778 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 66.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BROWN MICHAEL JON | Officer | 16 Mar 2026 | Automatic sell (-) | 1,700 | 66.34 | 112,778 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management |
| 27 Jan 2026 | Announcement | Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time. |
| 12 Jan 2026 | Announcement | Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook |
| 07 Jan 2026 | Announcement | Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |